Kenneth Romanzi named CEO of Nature's Sunshine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2025
0mins
Should l Buy NATR?
Leadership Change: Nature's Sunshine Products (NATR) has appointed Kenneth Romanzi as the new Chief Executive Officer, succeeding Terrence Moorehead.
Effective Date: Romanzi will officially take on the role and join the Board of Directors on October 29, 2025.
Previous Experience: Prior to this appointment, Romanzi was the President, CEO, and a Board member at B&G Foods (BGS).
Board Membership: Along with his CEO role, Romanzi will also become a member of the Nature's Sunshine Board of Directors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NATR
Wall Street analysts forecast NATR stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 27.500
Low
22.00
Averages
22.50
High
23.00
Current: 27.500
Low
22.00
Averages
22.50
High
23.00
About NATR
Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nature's Sunshine Stock Soars 63.7% Amid Mixed Outlook
- Impressive Stock Performance: Nature's Sunshine's stock has surged by 63.7% over the past six months, reaching a new 52-week high of $27.62 per share, reflecting market optimism about its short-term performance, yet raising concerns about long-term growth potential.
- Weak Revenue Growth: Despite a solid quarterly performance, the company's compounded annual growth rate over the past three years stands at only 2.8%, significantly below industry standards, indicating a lack of long-term sales growth capability that may undermine investor confidence.
- Limited Distribution Channels: With $474.5 million in revenue over the past year, Nature's Sunshine operates as a small consumer staples company, which places it at a disadvantage in negotiations with larger competitors, thereby restricting its market potential and growth opportunities.
- Dismal Future Growth Projections: Wall Street analysts forecast a mere 3.1% revenue growth for Nature's Sunshine over the next 12 months, suggesting that its new products are unlikely to drive significant sales increases, which may lead investors to adopt a cautious stance regarding its future performance.
See More
Doseology Sciences Launches New Caffeine Pouches Amid Market Shift
- Market Transformation: The functional market is projected to grow from $164 billion to $240 billion, indicating strong consumer demand for practical products, positioning Doseology Sciences at the heart of this high-growth cycle.
- New Product Pilot: Doseology began pilot production of caffeine energy pouches in January 2026, utilizing a nicotine-free, portable format aimed at meeting consumer demand for alternative energy drinks, which is expected to enhance market competitiveness.
- Brand Acquisition: In December 2024, Doseology acquired the Feed That Brain brand for $400,000, strengthening its position in the rapidly growing energy drink and sugar-free alternatives market, facilitating future product innovation.
- Strategic Advisor Appointment: The company appointed Joseph Mimran as a strategic advisor under a three-year contract valued at $400,000, aiming to leverage his industry experience to drive product development and market compliance, further enhancing Doseology's market influence.
See More
Doseology Launches Innovative Energy Product Line
- Market Growth Potential: The functional market is projected to expand from $164 billion to over $240 billion, indicating strong consumer demand for utility-driven products, positioning Doseology at the forefront of this high-growth cycle.
- New Product Pilot: Doseology initiated pilot production of caffeine-based energy pouches in January 2026, utilizing nicotine-free portable packaging to meet consumer demand for healthier alternatives, which is expected to significantly enhance market competitiveness.
- Strategic Brand Acquisition: Doseology acquired the Feed That Brain brand for $400,000, integrating functional product design with market trends to strengthen its position in the energy drink and alternative caffeine product sectors.
- Executive Recruitment: The company appointed Joseph Mimran as Strategic Advisor with a three-year contract valued at $400,000, aiming to leverage his extensive retail experience to drive Doseology's product development and market expansion.
See More
Synergy Worldwide's Pro-Argi-9+ Named #1 L-Arginine Supplement by Euromonitor
- Global Recognition: Synergy Worldwide's Pro-Argi-9+ has been named the world's #1 L-arginine supplement by Euromonitor International, reinforcing the product's leadership in the health and wellness sector and is expected to drive sales growth.
- Scientific Formula: Pro-Argi-9+ features clinically researched ingredients, combining L-arginine and L-citrulline to enhance nitric oxide production, thereby improving blood circulation and boosting overall health and vitality for users.
- Market Impact: This certification not only elevates Pro-Argi-9+'s market visibility but also attracts more consumers to Synergy's science-based nutritional solutions, helping the company stand out in the competitive dietary supplement market.
- Leadership Showcase: Executives at Synergy Worldwide noted that the success of Pro-Argi-9+ reflects the company's marketing efforts and leadership globally, which is expected to further enhance brand loyalty and market share.
See More
Synergy Worldwide's Pro-Argi-9+ Named World's #1 L-Arginine Supplement
- Global Recognition: Synergy Worldwide's Pro-Argi-9+ has been named the world's #1 L-arginine supplement by Euromonitor International, reinforcing its leadership in the health and wellness sector and likely driving sales growth while enhancing brand influence.
- Scientific Formula: Pro-Argi-9+ features clinically researched ingredients, combining L-arginine and L-citrulline to boost nitric oxide production, thereby improving blood circulation and overall health, aligning with market demand for effective nutritional supplements.
- Market Potential: This certification not only enhances product recognition but also motivates Synergy Worldwide to further promote Pro-Argi-9+ across Asia-Pacific and globally to meet the rising health demands, thereby increasing customer loyalty.
- Corporate Mission: Synergy Worldwide remains committed to advancing health through science-based nutrition, with the success of Pro-Argi-9+ serving as a cornerstone for future innovation and product excellence, aiding its expansion in the global market.
See More
Two High-Risk Stocks That Could Plummet This Quarter
Coca-Cola Consolidated Inc Performance: The company reported a year-over-year increase in third-quarter financial results, with a stock gain of around 22% over the past month and an RSI value of 88.5, indicating it may be overbought.
Nature’s Sunshine Products Growth: Nature’s Sunshine reported better-than-expected third-quarter results, raising its FY25 sales guidance, with a stock increase of approximately 45% in five days and an RSI value of 81.1, also suggesting overbought conditions.
Momentum Indicator Explanation: The Relative Strength Index (RSI) is a momentum indicator that helps traders assess stock performance by comparing price strength on up days versus down days, with values above 70 indicating overbought conditions.
Investor Caution Advised: Both Coca-Cola Consolidated and Nature’s Sunshine Products are highlighted as potentially risky investments for momentum-focused traders due to their high RSI values.
See More
Nature's Sunshine Stock Soars 63.7% Amid Mixed Outlook
- Impressive Stock Performance: Nature's Sunshine's stock has surged by 63.7% over the past six months, reaching a new 52-week high of $27.62 per share, reflecting market optimism about its short-term performance, yet raising concerns about long-term growth potential.
- Weak Revenue Growth: Despite a solid quarterly performance, the company's compounded annual growth rate over the past three years stands at only 2.8%, significantly below industry standards, indicating a lack of long-term sales growth capability that may undermine investor confidence.
- Limited Distribution Channels: With $474.5 million in revenue over the past year, Nature's Sunshine operates as a small consumer staples company, which places it at a disadvantage in negotiations with larger competitors, thereby restricting its market potential and growth opportunities.
- Dismal Future Growth Projections: Wall Street analysts forecast a mere 3.1% revenue growth for Nature's Sunshine over the next 12 months, suggesting that its new products are unlikely to drive significant sales increases, which may lead investors to adopt a cautious stance regarding its future performance.
See More
Doseology Sciences Launches New Caffeine Pouches Amid Market Shift
- Market Transformation: The functional market is projected to grow from $164 billion to $240 billion, indicating strong consumer demand for practical products, positioning Doseology Sciences at the heart of this high-growth cycle.
- New Product Pilot: Doseology began pilot production of caffeine energy pouches in January 2026, utilizing a nicotine-free, portable format aimed at meeting consumer demand for alternative energy drinks, which is expected to enhance market competitiveness.
- Brand Acquisition: In December 2024, Doseology acquired the Feed That Brain brand for $400,000, strengthening its position in the rapidly growing energy drink and sugar-free alternatives market, facilitating future product innovation.
- Strategic Advisor Appointment: The company appointed Joseph Mimran as a strategic advisor under a three-year contract valued at $400,000, aiming to leverage his industry experience to drive product development and market compliance, further enhancing Doseology's market influence.
See More
Doseology Launches Innovative Energy Product Line
- Market Growth Potential: The functional market is projected to expand from $164 billion to over $240 billion, indicating strong consumer demand for utility-driven products, positioning Doseology at the forefront of this high-growth cycle.
- New Product Pilot: Doseology initiated pilot production of caffeine-based energy pouches in January 2026, utilizing nicotine-free portable packaging to meet consumer demand for healthier alternatives, which is expected to significantly enhance market competitiveness.
- Strategic Brand Acquisition: Doseology acquired the Feed That Brain brand for $400,000, integrating functional product design with market trends to strengthen its position in the energy drink and alternative caffeine product sectors.
- Executive Recruitment: The company appointed Joseph Mimran as Strategic Advisor with a three-year contract valued at $400,000, aiming to leverage his extensive retail experience to drive Doseology's product development and market expansion.
See More
Synergy Worldwide's Pro-Argi-9+ Named #1 L-Arginine Supplement by Euromonitor
- Global Recognition: Synergy Worldwide's Pro-Argi-9+ has been named the world's #1 L-arginine supplement by Euromonitor International, reinforcing the product's leadership in the health and wellness sector and is expected to drive sales growth.
- Scientific Formula: Pro-Argi-9+ features clinically researched ingredients, combining L-arginine and L-citrulline to enhance nitric oxide production, thereby improving blood circulation and boosting overall health and vitality for users.
- Market Impact: This certification not only elevates Pro-Argi-9+'s market visibility but also attracts more consumers to Synergy's science-based nutritional solutions, helping the company stand out in the competitive dietary supplement market.
- Leadership Showcase: Executives at Synergy Worldwide noted that the success of Pro-Argi-9+ reflects the company's marketing efforts and leadership globally, which is expected to further enhance brand loyalty and market share.
See More
Synergy Worldwide's Pro-Argi-9+ Named World's #1 L-Arginine Supplement
- Global Recognition: Synergy Worldwide's Pro-Argi-9+ has been named the world's #1 L-arginine supplement by Euromonitor International, reinforcing its leadership in the health and wellness sector and likely driving sales growth while enhancing brand influence.
- Scientific Formula: Pro-Argi-9+ features clinically researched ingredients, combining L-arginine and L-citrulline to boost nitric oxide production, thereby improving blood circulation and overall health, aligning with market demand for effective nutritional supplements.
- Market Potential: This certification not only enhances product recognition but also motivates Synergy Worldwide to further promote Pro-Argi-9+ across Asia-Pacific and globally to meet the rising health demands, thereby increasing customer loyalty.
- Corporate Mission: Synergy Worldwide remains committed to advancing health through science-based nutrition, with the success of Pro-Argi-9+ serving as a cornerstone for future innovation and product excellence, aiding its expansion in the global market.
See More
Two High-Risk Stocks That Could Plummet This Quarter
Coca-Cola Consolidated Inc Performance: The company reported a year-over-year increase in third-quarter financial results, with a stock gain of around 22% over the past month and an RSI value of 88.5, indicating it may be overbought.
Nature’s Sunshine Products Growth: Nature’s Sunshine reported better-than-expected third-quarter results, raising its FY25 sales guidance, with a stock increase of approximately 45% in five days and an RSI value of 81.1, also suggesting overbought conditions.
Momentum Indicator Explanation: The Relative Strength Index (RSI) is a momentum indicator that helps traders assess stock performance by comparing price strength on up days versus down days, with values above 70 indicating overbought conditions.
Investor Caution Advised: Both Coca-Cola Consolidated and Nature’s Sunshine Products are highlighted as potentially risky investments for momentum-focused traders due to their high RSI values.
See More
